Incyte INCY OLUMIANT Royalty Revenues — Total revenues
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Incyte in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Incyte’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Incyte's olumiant royalty revenues — total revenues.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Incyte's OLUMIANT royalty revenues — total revenues?
- Incyte (INCY) reported OLUMIANT royalty revenues — total revenues of $36.41M in Q1 2026.
- How has Incyte's OLUMIANT royalty revenues — total revenues changed year-over-year?
- Incyte's OLUMIANT royalty revenues — total revenues increased by 18.2% year-over-year, from $30.8M to $36.41M.
- What does OLUMIANT royalty revenues — total revenues mean?
- This metric represents the total gross royalty income recognized by the company from the licensing of a pharmaceutical product to a third-party partner. It reflects the commercial performance of the drug in the market as reported by the licensee, serving as a key indicator of the company's passive revenue stream from intellectual property. This revenue is typically calculated as a percentage of the partner's net sales of the licensed therapeutic.